The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).
 
Andrew David Seidman
No Relationships to Disclose
 
Meredith M. Regan
Consulting or Advisory Role - Ipsen (Inst); Merck
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); OncoGenex (Inst); Pfizer (Inst); Pierre Fabre (Inst); Veridex (Inst)
 
Dawn L. Hershman
No Relationships to Disclose
 
Larissa A. Korde
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
 
Jane Perlmutter
No Relationships to Disclose
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Larry Rubinstein
No Relationships to Disclose
 
Louis Fehrenbacher
Research Funding - Roche/Genentech (Inst)
 
Julia A. Beaver
No Relationships to Disclose
 
Laleh Amiri-Kordestani
No Relationships to Disclose
 
Suparna B. Wedam
No Relationships to Disclose
 
Mary Lou Smith
Research Funding - Celgene (Inst); Genentech (Inst); Genomic Health (Inst)
Travel, Accommodations, Expenses - GHI Pharma; Novartis
 
Priya Rastogi
No Relationships to Disclose
 
Louise Bordeleau
Consulting or Advisory Role - Amgen; Pfizer
 
Lynn Pearson Butler
No Relationships to Disclose
 
Jennifer Fallas Hayes
No Relationships to Disclose
 
Jo Anne Zujewski
No Relationships to Disclose